BRIEF published on 11/03/2026 at 13:39, 3 days 13 hours ago UZEDY®: Significant increase in sales in the United States in 2026 Sales Growth Teva Pharmaceuticals UZEDY Sales Revised Forecasts Medincell Royalties
BRIEF published on 11/03/2026 at 13:39, 3 days 13 hours ago Medincell Reports Significant Growth in UZEDY® Sales Q3 Financial Results Medincell Teva Pharmaceuticals UZEDY® Long-acting Injectables
PRESS RELEASE published on 11/03/2026 at 13:34, 3 days 13 hours ago Inside Information / Other news releases
BRIEF published on 10/13/2026 at 18:15, 24 days 8 hours ago Medincell strengthens its financing with a new non-dilutive loan Treasury Funding Biopharmaceutical Medincell Non-dilutable
BRIEF published on 10/13/2026 at 18:15, 24 days 8 hours ago Medincell Secures €41.8 Million in Non-Dilutive Financing Debt Maturity Non-dilutive Financing Biopharmaceuticals European Investment Bank Medincell
PRESS RELEASE published on 10/13/2026 at 18:10, 24 days 8 hours ago Inside Information / Other news releases Medincell secures €13.8 million non-dilutive financing, totaling €41.8 million. Debt maturity extended through 2031. No equity instruments used for financing Debt Maturity Non-dilutive Financing Bpifrance Medincell European Commercial Banks
BRIEF published on 10/09/2026 at 15:03, 28 days 11 hours ago Medincell shares resume trading on Euronext Paris FDA Euronext Medincell Teva Olanzapine LAI
BRIEF published on 10/09/2026 at 15:03, 28 days 11 hours ago Medincell Resumes Trading on Euronext Paris Euronext Paris FDA Approval Trading Resumption Medincell BEPO Technology
PRESS RELEASE published on 10/09/2026 at 14:58, 28 days 11 hours ago Inside Information / Other news releases Medincell resumes trading on Euronext Paris after temporary suspension. The company specializes in long-acting injectable treatments using innovative technologies Innovation Euronext Paris Trading Medincell Long-acting Injectable Treatments
BRIEF published on 10/09/2026 at 14:01, 28 days 12 hours ago Medincell receives FDA approval for WELTRUZA™ FDA Schizophrenia Medincell Olanzapine WELTRUZA™
Published on 11/06/2026 at 22:15, 4 hours 29 minutes ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 13 hours 44 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 14 hours 14 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 14 hours 14 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 20:15, 6 hours 29 minutes ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 19:15, 7 hours 29 minutes ago EQS-Adhoc: ABO Energy GmbH & Co. KGaA suspends the interest payment on the bond 2024/2029 due on 8 November 2026.
Published on 11/06/2026 at 19:00, 7 hours 44 minutes ago Finexity AG: FINEXITY issues 2026/2030 bond with a minimum of 7.00% p.a. – either conventionally in a securities account or as a crypto security in a wallet
Published on 11/06/2026 at 18:32, 8 hours 12 minutes ago EQS-Adhoc: Finexity AG: FINEXITY issues 2026/2030 bond
Published on 11/06/2026 at 18:00, 8 hours 44 minutes ago ARVERNE GROUP: Number shares and voting rights
Published on 11/06/2026 at 18:00, 8 hours 44 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 11/06/2026 at 17:54, 8 hours 50 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 9 hours 9 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
